Fractyl Health (NASDAQ:GUTS) Director Acquires $49,999.89 in Stock

Fractyl Health, Inc. (NASDAQ:GUTS) Director William Bradley acquired 68,493 shares of the business’s stock in a transaction dated Wednesday, June 10th. The stock was bought at an average cost of $0.73 per share, with a total value of $49,999.89. Following the acquisition, the director owned 84,622 shares in the company, valued at $61,774.06. The trade was a 424.66% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Fractyl Health Stock Up 17.4%

GUTS opened at $0.85 on Friday. Fractyl Health, Inc. has a 1-year low of $0.38 and a 1-year high of $2.45. The stock’s fifty day simple moving average is $0.69 and its 200 day simple moving average is $1.07. The company has a current ratio of 4.28, a quick ratio of 4.28 and a debt-to-equity ratio of 1.41. The stock has a market cap of $134.85 million, a PE ratio of -0.66 and a beta of 2.34.

Fractyl Health (NASDAQ:GUTS) last posted its quarterly earnings data on Tuesday, May 12th. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.23. As a group, research analysts expect that Fractyl Health, Inc. will post -0.6 earnings per share for the current year.

Analyst Upgrades and Downgrades

GUTS has been the topic of a number of recent analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Fractyl Health in a research report on Tuesday, May 12th. HC Wainwright restated a “buy” rating and issued a $8.00 price target on shares of Fractyl Health in a research report on Thursday, June 4th. Wall Street Zen upgraded Fractyl Health from a “strong sell” rating to a “hold” rating in a research report on Saturday, May 16th. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $8.00 price target on shares of Fractyl Health in a research report on Thursday, March 26th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Fractyl Health has an average rating of “Hold” and a consensus target price of $5.40.

Institutional Trading of Fractyl Health

Several large investors have recently bought and sold shares of GUTS. FNY Investment Advisers LLC acquired a new stake in Fractyl Health in the third quarter valued at about $31,000. Jane Street Group LLC acquired a new stake in Fractyl Health in the second quarter valued at about $31,000. Accredited Investors Inc. acquired a new stake in Fractyl Health in the first quarter valued at about $46,000. Scientech Research LLC acquired a new stake in Fractyl Health in the third quarter valued at about $49,000. Finally, Prelude Capital Management LLC acquired a new stake in Fractyl Health in the third quarter valued at about $55,000.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.